Pacira BioSciences, Inc. Revenue 2009–2025
Pacira BioSciences, Inc. reported $726.41M of revenue for fiscal 2025. That was 3.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +69.1%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $726.41M | +3.6% |
| FY 2024 | $700.97M | +3.9% |
| FY 2023 | $674.98M | +1.2% |
| FY 2022 | $666.82M | +23.1% |
| FY 2021 | $541.53M | +26.0% |
| FY 2020 | $429.65M | +2.0% |
| FY 2019 | $421.03M | +24.8% |
| FY 2018 | $337.28M | +17.7% |
| FY 2017 | $286.63M | +3.7% |
| FY 2016 | $276.37M | +11.0% |
| FY 2015 | $249.00M | +26.0% |
| FY 2014 | $197.67M | +131.1% |
| FY 2013 | $85.55M | +118.9% |
| FY 2012 | $39.08M | +149.1% |
| FY 2011 | $15.69M | +7.7% |
| FY 2010 | $14.56M | -3.0% |
| FY 2009 | $15.01M | — |
Source: Pacira BioSciences, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PCRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Pacira BioSciences, Inc. reported $726.41M of revenue for fiscal 2025. That was 3.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +69.1%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Pacira BioSciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePacira BioSciences, Inc. — frequently asked questions
What is Pacira BioSciences, Inc.'s revenue?
Pacira BioSciences, Inc. (PCRX) reported revenue of $726.41M for fiscal year 2025, per its SEC filings.
How has Pacira BioSciences, Inc.'s revenue changed over time?
Between fiscal 2009 and 2025, PCRX's revenue grew at roughly 27.4% per year (compound annual rate), from $15.01M to $726.41M.
Where does this data come from?
Figures are computed from Pacira BioSciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.